Top25-SA-Banner

Cantor Fitzgerald Thinks Aimmune Therapeutics’ Stock is Going to Recover


Cantor Fitzgerald analyst William Tanner reiterated a Buy rating on Aimmune Therapeutics (NASDAQ: AIMT) today and set a price target of $62. The company’s shares opened today at $26.39, close to its 52-week low of $24.56.

Tanner said:

“: We reiterate the Overweight rating and $62 PT for AIMT stock. Clinical data support the notion, in our view, that AR101 is safe and effective for treating hypersensitivity to peanut protein and that, given the unmet medical need, it could become an important treatment for the condition. With proof of concept demonstrated for the company’s ImmunoTherapy (CODIT) regimen, we believe investors should consider the potential that CODIT could be useful for treating other food-related hypersensitivities such as egg and walnut.”

According to TipRanks.com, Tanner is a 2-star analyst with an average return of 0.6% and a 43.8% success rate. Tanner covers the Healthcare sector, focusing on stocks such as Supernus Pharmaceuticals, Intra-Cellular Therapies, and Evofem Biosciences Inc.

Currently, the analyst consensus on Aimmune Therapeutics is a Strong Buy with an average price target of $53.75, a 103.7% upside from current levels. In a report issued on October 9, Roth Capital also reiterated a Buy rating on the stock with a $80 price target.

.

See today’s analyst top recommended stocks >>

Based on Aimmune Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $52.55 million. In comparison, last year the company had a GAAP net loss of $31.79 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.

From Our Partners